Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, has reported an impressive 16% year-over-year revenue growth for the second quarter of fiscal year 2026, with total revenue from operations reaching Rs. 5,880 million. This performance reflects the company’s strong momentum, particularly in its non-generic pharmaceutical (non-GPL) business, which achieved a remarkable 39.7% YoY growth. For the first half of FY26, Alivus recorded revenues of Rs. 11,898 million, marking an 8.6% increase compared to the previous year. The company also highlighted a significant rise in its EBITDA, which climbed to Rs. 1,939 million, showcasing a 35.7% YoY growth and an increase in EBITDA margins to 33.0%, up 480 basis points from the previous year.

The net profit after tax (PAT) for Q2FY26 stood at Rs. 1,301 million, reflecting a 36.5% increase YoY, with PAT margins reaching 22.1%—a gain of 330 basis points. For the first half, PAT was reported at Rs. 2,516 million, showing a 21.7% growth YoY. The company also generated a robust free cash flow of Rs. 1,477 million during this period, resulting in cash and cash equivalents of Rs. 6,526 million as of September 30, 2025. Analysts and executives, including MD & CEO Dr. Yasir Rawjee, expressed confidence in the company’s ability to maintain strong performance into the second half of the fiscal year, driven by continued demand across key global markets.

Alivus Life Sciences is focused on the development and manufacture of high-value Active Pharmaceutical Ingredients (APIs) and is expanding its capabilities in contract development and manufacturing organization (CDMO) services. With a diversified portfolio of 170 molecules, the company is making strides in various therapeutic areas, including cardiovascular and central nervous system diseases. In addition to its growth in revenue and profit margins, Alivus is progressing on its Phase 1 construction work for a new facility in Solapur, which will enhance its production capacity. The company remains optimistic about sustaining its margins above 30%, despite the absence of benefits from the Production-Linked Incentive (PLI) scheme, bolstered by a solid pipeline of new launches and operational efficiencies.